Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.

Cesini L, Carmosino I, Breccia M, De Benedittis D, Mohamed S, De Luca ML, Colafigli G, Molica M, Scalzulli E, Massaro F, Mariggiò E, Rizzo L, Loglisci MG, Scamuffa MC, Vozella F, Diverio D, Mancini M, Alimena G, Foà R, Latagliata R.

Oncol Res Treat. 2019 Oct 8:1-5. doi: 10.1159/000502801. [Epub ahead of print]

PMID:
31593970
2.

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R.

Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110. [Epub ahead of print]

PMID:
29896890
3.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Ricciardi MR, Salvestrini V, Licchetta R, Mirabilii S, Forcato M, Gugliotta G, Salati S, Castagnetti F, Rosti G, Breccia M, Alimena G, Manfredini R, Bicciato S, Lemoli RM, Tafuri A.

Oncotarget. 2018 Apr 24;9(31):21758-21769. doi: 10.18632/oncotarget.24938. eCollection 2018 Apr 24.

4.

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R.

Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.

5.

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Molica M, Canichella M, Colafigli G, Latagliata R, Diverio D, Alimena G, Foà R, Breccia M.

Br J Haematol. 2018 Aug;182(3):427-429. doi: 10.1111/bjh.14783. Epub 2017 Jul 5. No abstract available.

PMID:
28677850
6.

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.

Latagliata R, Montanaro M, Cedrone M, Di Veroli A, Spirito F, Santoro C, Leonetti Crescenzi S, Porrini R, Di Giandomenico J, Villivà N, Spadea A, Rago A, De Gregoris C, Romano A, Anaclerico B, De Muro M, Felici S, Breccia M, Montefusco E, Bagnato A, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A; Gruppo Laziale, SMPC Ph1.

Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.

PMID:
28662484
7.

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.

Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG.

Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23.

8.

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

PMID:
28509339
9.

Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline.

Breccia M, Arboscello E, Bellodi A, Colafigli G, Molica M, Bergamaschi M, Massaro F, Quattrocchi L, Sarocchi M, Spallarossa P, Alimena G.

Crit Rev Oncol Hematol. 2016 Nov;107:190-198. doi: 10.1016/j.critrevonc.2016.10.002. Epub 2016 Oct 15. Review.

PMID:
27823647
10.

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F.

Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12.

11.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

12.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

13.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

14.

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.

Breccia M, Molica M, Colafigli G, Massaro F, Alimena G.

Leuk Res. 2016 Sep;48:20-5. doi: 10.1016/j.leukres.2016.06.010. Epub 2016 Jul 1. Review.

PMID:
27442893
15.

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G.

Support Care Cancer. 2016 Nov;24(11):4487-93. doi: 10.1007/s00520-016-3286-z. Epub 2016 Jun 3.

PMID:
27260015
16.

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G.

Haematologica. 2016 Jun;101(6):e267-8. doi: 10.3324/haematol.2016.145623. Epub 2016 May 31. No abstract available.

17.

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.

Perrone S, Massaro F, Alimena G, Breccia M.

Expert Opin Pharmacother. 2016 Aug;17(11):1517-26. doi: 10.1080/14656566.2016.1190335. Epub 2016 Jun 3. Review.

PMID:
27231757
18.

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib.

Breccia M, Colafigli G, Quattrocchi L, Abruzzese E, Alimena G.

Mediterr J Hematol Infect Dis. 2016 Feb 20;8(1):e2016016. doi: 10.4084/MJHID.2016.016. eCollection 2016. No abstract available.

19.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. Epub 2016 Apr 24.

20.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

21.

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Breccia M, Colafigli G, Molica M, Alimena G.

Expert Opin Drug Saf. 2016;15(4):525-33. doi: 10.1517/14740338.2016.1145654. Epub 2016 Feb 16. Review.

PMID:
26799331
22.

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.

Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F.

Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269.

23.

Ponatinib in chronic myeloid leukaemia: ready for first-line?

Breccia M, Alimena G.

Lancet Haematol. 2015 Sep;2(9):e352-3. doi: 10.1016/S2352-3026(15)00130-1. Epub 2015 Jul 30. No abstract available.

PMID:
26685767
24.

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.

Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G.

Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9.

PMID:
26648184
25.

Dasatinib first-line: Multicentric Italian experience outside clinical trials.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G.

Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17.

PMID:
26643920
26.

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.

Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G.

Br J Haematol. 2016 Jul;174(1):160-2. doi: 10.1111/bjh.13758. Epub 2015 Oct 28. No abstract available.

PMID:
26507357
27.

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Breccia M, Colafigli G, Molica M, De Angelis F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Alimena G.

Br J Haematol. 2016 Jun;173(6):945-6. doi: 10.1111/bjh.13649. Epub 2015 Aug 25. No abstract available.

PMID:
26304741
28.

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.

Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G.

Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14.

PMID:
26282944
29.

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.

Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G.

Eur J Haematol. 2016 Jun;96(6):643-9. doi: 10.1111/ejh.12674. Epub 2015 Sep 18.

PMID:
26277477
30.

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Haematologica. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25.

31.

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.

PMID:
26088952
32.

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.

Andriani A, Montanaro M, Voso MT, Villivà N, Ciccone F, Andrizzi C, De Gregoris C, Di Veroli A, Maurillo L, Alimena G, Latagliata R.

Leuk Res. 2015 Aug;39(8):801-4. doi: 10.1016/j.leukres.2015.03.001. Epub 2015 Mar 19.

PMID:
26065981
33.

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.

Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, Montagna C, Volpicelli P, De Angelis F, Petrucci L, Serrao A, Molica M, Salaroli A, Diverio D, Alimena G.

Leuk Lymphoma. 2016;57(1):99-102. doi: 10.3109/10428194.2015.1043548. Epub 2015 Oct 5.

PMID:
25997497
34.

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Breccia M, Molica M, Colafigli G, Alimena G.

Expert Rev Hematol. 2015 Aug;8(4):387-9. doi: 10.1586/17474086.2015.1041494. Epub 2015 Apr 27.

PMID:
25915176
35.

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).

Morano SG, Latagliata R, Girmenia C, Massaro F, Berneschi P, Guerriero A, Giampaoletti M, Sammarco A, Annechini G, Fama A, Di Rocco A, Chistolini A, Micozzi A, Molica M, Barberi W, Minotti C, Brunetti GA, Breccia M, Cartoni C, Capria S, Rosa G, Alimena G, Foà R.

Support Care Cancer. 2015 Nov;23(11):3289-95. doi: 10.1007/s00520-015-2740-7. Epub 2015 Apr 26.

PMID:
25910751
36.

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Breccia M, Molica M, Colafigli G, Alimena G.

Acta Haematol. 2015;134(1):57-8. doi: 10.1159/000370098. Epub 2015 Apr 11. No abstract available.

PMID:
25870940
37.

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N.

Leukemia. 2015 Jun;29(6):1344-9. doi: 10.1038/leu.2015.87. Epub 2015 Mar 24.

PMID:
25801912
38.

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.

Breccia M, Voso MT, Aloe Spiriti MA, Fenu S, Maurillo L, Buccisano F, Tafuri A, Alimena G.

Ann Hematol. 2015 May;94(5):771-7. doi: 10.1007/s00277-015-2341-z. Epub 2015 Mar 7. Review.

PMID:
25743685
39.

Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.

Breccia M, Colafigli G, Molica M, Alimena G.

Am J Hematol. 2015 May;90(5):E100-1. doi: 10.1002/ajh.23976. No abstract available.

40.

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.

Breccia M, Latagliata R, Molica M, Colafigli G, Mancini M, Diverio D, Tafuri A, Alimena G.

Am J Hematol. 2015 May;90(5):E95-6. doi: 10.1002/ajh.23972. Epub 2015 Mar 30. No abstract available.

41.

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.

Rago A, Latagliata R, Montanaro M, Montefusco E, Andriani A, Crescenzi SL, Mecarocci S, Spirito F, Spadea A, Recine U, Cicconi L, Avvisati G, Cedrone M, Breccia M, Porrini R, Villivà N, De Gregoris C, Alimena G, D'Arcangelo E, Guglielmelli P, Lo-Coco F, Vannucchi A, Cimino G.

Leuk Res. 2015 Mar;39(3):314-7. doi: 10.1016/j.leukres.2015.01.001. Epub 2015 Jan 12.

PMID:
25636356
42.

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.

Breccia M, Molica M, Colafigli G, Zacheo I, Latagliata R, Tafuri A, Alimena G.

Leuk Lymphoma. 2015 Jul;56(7):2206-7. doi: 10.3109/10428194.2014.993391. Epub 2015 Feb 9. No abstract available.

PMID:
25549804
43.

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

Breccia M, Molica M, Alimena G.

Leuk Res. 2014 Dec;38(12):1392-8. doi: 10.1016/j.leukres.2014.09.016. Epub 2014 Oct 5. Review.

PMID:
25449685
44.

Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach.

Breccia M, Alimena G.

Expert Rev Hematol. 2015 Feb;8(1):5-7. doi: 10.1586/17474086.2015.987230. Epub 2014 Nov 28.

PMID:
25431965
45.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.

Ann Oncol. 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.

PMID:
25361995
46.

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.

Latagliata R, Volpicelli P, Breccia M, Vozella F, Romano A, Montagna C, Molica M, Finsinger P, Carmosino I, Serrao A, Zacheo I, Santopietro M, Salaroli A, Alimena G.

Am J Hematol. 2015 Feb;90(2):105-8. doi: 10.1002/ajh.23879. Epub 2014 Nov 19.

47.

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.

Breccia M, Molica M, Zacheo I, Serrao A, Alimena G.

Ann Hematol. 2015 Mar;94(3):393-7. doi: 10.1007/s00277-014-2231-9. Epub 2014 Oct 12.

PMID:
25304102
48.

Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.

Molica M, Zacheo I, Diverio D, Alimena G, Breccia M.

Br J Haematol. 2015 Apr;169(1):148-50. doi: 10.1111/bjh.13184. Epub 2014 Oct 9. No abstract available.

PMID:
25296902
49.

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E.

BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9.

PMID:
25204541
50.

Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes.

Latagliata R, Alati C, Carmosino I, Montagna C, Romano A, Finsinger P, Vozella F, Volpicelli P, Breccia M, Alimena G, Oliva EN.

J Diabetes. 2015 Jul;7(4):493-6. doi: 10.1111/1753-0407.12203. Epub 2014 Oct 3.

PMID:
25060764

Supplemental Content

Loading ...
Support Center